22 July 2021
EMA/CHMP/266703/2021
Committee for Medicinal Products for Human Use (CHMP)

**Summary of opinion[1] (post authorisation)**

# Deltyba

delamanid

On 22 July 2021, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Deltyba. The marketing authorisation holder for this medicinal product is Otsuka Novel Products GmbH.

The CHMP adopted an extension to the indication for Deltyba as follows:[2]

> Deltyba is indicated for use as part of an appropriate combination regimen for pulmonary multi-drug resistant tuberculosis (MDR-TB) in adults, adolescents**,** ~~and~~ children **and infants** with a body weight of at least ~~30~~ **10** kg when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability.

The CHMP also recommended the addition of a new 25 mg dispersible tablet.

Detailed recommendations for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published in the revised European public assessment report (EPAR), and will be available in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission.

[1] Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days from adoption of the opinion
[2] New text in bold, removed text as strikethrough

**Official address** Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
**Address for visits and deliveries** Refer to www.ema.europa.eu/how-to-find-us
**Send us a question** Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union